| Angiogenesis is a fundamental driver of tumor biology and many other important aspect of human health. Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) has been shown to be a valuable biomarker for the indirect assessment of angiogenesis. However, DCE-MRI is very specialized technique that has limitations. In this dissertation new models and contrast agents to address some of these limitations are presented. Chapter 1 presents an introduction to DCE-MRI, the rationale to asses tumor biology with this technique, the MRI pulses sequences and the standard pharmacokinetic modeling used for the analysis of DCE-MRI data. Chapter 2 describes the application of DCE-MRI to asses the response to the hypoxia-activated drug TH-302. It is shown that DCE-MRI can detect a response after only 24 hours of initiating therapy. In Chapter 3, a new model for the analysis of DCE-MRI is presented, the so-called Linear Reference Region Model (LRRM). This new model improves upon existing models and it was demonstrated that it is ∼620 faster than current algorithms and 5 times less sensitive to noise, and more importantly less sensitive to temporal resolution which enables the analysis of DCE-MRI data obtained in the clinical setting, which opens a new area of study in clinical MRI. Chapter 4 describes the extension of the LRRM to estimate the absolute permeability of two fluorinated contrast agents; we call this approach the Reference Agent Model (RAM). In order to make this new model an experimental reality, a novel pulse sequence and contrast agents (CA) for 19F MRI were developed. Two contributions to the field of DCE-MRI are presented in this chapter, the first simultaneous 19F-DCE-MRI detection of two fluorinated CA in a mouse model of breast cancer, and the estimation of their relative permeability. RAM eliminates some of the physiological variables that affect DCE-MRI, which may improve its sensitivity and specificity. Finally, new potential applications of LRRM and RAM are discussed in Chapter 5. |
